



JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ARAI3A

In re Application of:)	Confirmation No.:
Norie ARAI et al.)	
)	Art Unit:
)	
Appln. No.: 10/765,905)	Examiner:
)	
Filed: January 29, 2004)	Washington, D.C.
)	
For: MUCOSAL IMMUNOREGULATORY)	August 18, 2004
AGENT AND ITS USE)	
)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

☒ B. before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate)

☐ A. Document(s) _____ is (are) U.S. patent(s) and/or published application(s). As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 U.S.C. §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (MPEP §609IIIA(2)(A)).

☐ B. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

☐ C. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)

Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449 (or PTO/SB/08A) from the files of the prior application(s) or a fresh PTO-1449 (or PTO/SB/08A) listing these documents, and request that they be considered and made of record in accordance with §1.98(d). Per

37 CFR §1.98(d), copies of these documents need not be filed in this application.

3. Document(s) AC-AF and AI-AK is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

☐ An English translation of each document _____ (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.

☒ A concise explanation of the relevance of document(s) AC-AF are found in the attached International search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

☐ A concise explanation of the relevance of document(s) _____ is set forth as follows:

(insert concise explanation of relevance)

☒ A concise explanation of the relevance of document(s) AI-AK can be found on page(s) 5 and 6 of the specification.

☐ A concise explanation of document(s) _____ can be found on the attached sheet.

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:


(insert other information)

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Jay M. Finkelstein
Reg. No. 21,082

JMF:lmh
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\S\SUMA\Arai3A\pto\ids.fee.doc

AUG 18 2004
U.S. PATENT & TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known

Application Number	10/765,905
Filing Date	29 January 2004
First Named Inventor	Norie ARAI et al
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	ARAI=3A

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code* Number* Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AC	JP 6-256219 A	9-13-1994			
	AD	JP 2000-07570 A	1-11-2000			
	AE	JP 2000-72579 A	3-7-2000			
	AF	JP 2000-93122 A	4-4-2000			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AG	AZUMA, and Yamamura, "Immunoadjuvants For Vaccine". Adv. Immunopharmacology. (1989), Vol. 4, pp. 149-158.	
	AH	GUILLEMARD, et al, "Simultaneous Production Of IFN- γ , IFN- α/β And Nitric Oxide In Peritoneal Macrophages From TDM-Treated Mice" Journal of Biological Regulators and Homeostatic Agents. (1998), Vol. 12, No. 4, pp. 106-111	
	AI	HASHIGUCHI, et al, "Cytokine secreted by Peyer's patch T cells and IgA production in intestine" Clinical Immunology (Rinsho-Meneki). (1998). Vol. 30, No. 11, pp. 1524-1531.	
	AJ	KIYONO, Clinical Immunology "IgA isotype regulation by mucosal T cells and epithelial cells" (Rinsho-Meneki). (1998), Vol. 30, No. 1, pp. 14-19.	
	AK	TAKAHASHI, Medical Immunology. "Mechanism for Mucosal Immunity to cholera" (1998), Vol. 27, No. 5-6, pp. 431-437.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.